[go: up one dir, main page]

US20040111150A1 - Medical device for delivering a therapeutic substance and method therefor - Google Patents

Medical device for delivering a therapeutic substance and method therefor Download PDF

Info

Publication number
US20040111150A1
US20040111150A1 US10/727,534 US72753403A US2004111150A1 US 20040111150 A1 US20040111150 A1 US 20040111150A1 US 72753403 A US72753403 A US 72753403A US 2004111150 A1 US2004111150 A1 US 2004111150A1
Authority
US
United States
Prior art keywords
therapeutic
group
stent
porous material
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/727,534
Inventor
Eric Berg
Thomas Dinh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Vascular Inc
Original Assignee
Medtronic Vascular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Vascular Inc filed Critical Medtronic Vascular Inc
Priority to US10/727,534 priority Critical patent/US20040111150A1/en
Publication of US20040111150A1 publication Critical patent/US20040111150A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/007—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate

Definitions

  • This invention relates to a medical device employing a therapeutic substance as a component thereof.
  • a therapeutic substance such as heparin
  • heparin may be included with a device and delivered locally in the coronary artery.
  • a method for making a medical device capable of localized application of therapeutic substances.
  • Medical devices which serve as substitute blood vessels, synthetic and intraocular lenses, electrodes, catheters and the like in and on the body or as extracorporeal devices intended to be connected to the body to assist in surgery or dialysis are well known.
  • intravascular procedures can bring medical devices into contact with the patient's vasculature.
  • percutaneous transluminal coronary angioplasty PTCA
  • Other intravascular invasive therapies include atherectomy (mechanical systems to remove plaque residing inside an artery), laser ablative therapy and the like.
  • atherectomy mechanical systems to remove plaque residing inside an artery
  • laser ablative therapy and the like.
  • restenosis at the site of a prior invasive coronary artery disease therapy occurs in a majority of cases.
  • Restenosis defined angiograhpically, is the recurrence of a 50% or greater narrowing of a luminal diameter at the site of a prior coronary artery disease therapy, such as a balloon dilatation in the case of PTCA therapy.
  • an intra-luminal component of restenosis develops near the end of the healing process initiated by vascular injury, which then contributes to the narrowing of the luminal diameter.
  • intimal hyperplasia This phenomenon is sometimes referred to as “intimal hyperplasia.” It is believed that a variety of biologic factors are involved in restenosis, such as the extent of the injury, platelets, inflammatory cells, growth factors, cytokines, endothelial cells, smooth muscle cells, and extracellular matrix production, to name a few.
  • Attempts to inhibit or diminish restenosis often include additional interventions such as the use of intravascular stents and the intravascular administration of pharmacological therapeutic agents.
  • such stents employing therapeutic substances such as glucocorticoids (e.g.
  • immobilization of heparin to a biomaterial surface consists of activating the material in such away that coupling between the biomaterial and finctional groups on the heparin (—COOH, —OH, —NH 2 ) can be achieved.
  • Larm presented in U.S. Pat. No. 4,613,665 a method to activate heparin via a controlled nitrous acid degradation step, resulting in degraded heparin molecules of which a part contains a free terminal aldehyde group.
  • Heparin in this form can be covalently bound to an aminated surface in a reductive animation process.
  • the molecule is degraded and as a result shows less catalytic activity in solution, the end point attachment of this type of heparin to a surface results in true anti-thromogenicity due to the proper presentation of the biomolecule to the surface. In this fashion, the molecule is freely interacting with AT-III and the coagulation enzymes, preventing the generation of thrombi and microemboli.
  • This invention relates to a medical device having a blood-contacting surface with a therapeutic substance thereon.
  • the device according to the invention is capable of applying a highly localized therapeutic material into a body lumen to treat or prevent injury.
  • the term “injury” means a trauma, that may be incidental to surgery or other treatment methods including deployment of a stent, or a biologic disease, such as an immune response or cell proliferation caused by the administration of growth factors.
  • the methods of the invention may be performed in anticipation of “injury” as a prophylactic.
  • a prophylactic treatment is one that is provided in advance of any symptom of injury in order to prevent injury, prevent progression of injury or attenuate any subsequent onset of a symptom of such injury.
  • a device for delivery of localized therapeutic material includes a structure including a porous material and a plurality of discrete particles of a water-insoluble salt of the therapeutic material dispersed throughout a substantial portion of the porous material.
  • the device is capable of being implanted in a body so that the localized therapeutic agent can be delivered in vivo, typically at a site of vascular injury or trauma.
  • the porous material is also biocompatible, sufficiently tear resistant and nonthrombogenic.
  • the porous material may be a film on at least a portion of the structure or the porous material may be an integral portion of the structure.
  • the porous material is selected from the group of a natural hydrogel, a synthetic hydrogel, teflon, silicone, polyurethane, polysulfone, cellulose, polyethylene, polypropylene, polyamide, polyester, polytetrafluoroethylene, and a combination of two or more of these materials.
  • natural hydrogels include fibrin, collagen, elastin, and the like.
  • the therapeutic agent preferably includes an antithrombotic material. More preferably, the antithrombotic material is a heparin or heparin derivative or analog. Also preferably, the insoluble salt of the therapeutic material is one of the silver, barium or calcium salts of the material.
  • the structure of the device can be adapted for its intended extracorporeal or intravascular purpose in an internal human body site, such as an artery, vein, urethra, other body lumens, cavities, and the like or in an extracorporeal blood pump, blood filter, blood oxygenator or tubing.
  • the shape is preferably generally cylindrical, and more preferably, the shape is that of a catheter, a stent, or a guide wire.
  • an implantable device capable of delivery of a therapeutic material includes a structure comprising a porous material; and a plurality of discrete particles comprising a heavy metal water soluble salt dispersed throughout a substantial portion of the porous material.
  • the heavy metal water-soluble salt is selected from the group of AgNO 3 , Ba(NO 3 ) 2 , BaCl 2 , and CaCl 2 .
  • the amount of water-soluble salt dispersed throughout a portion of the porous material determines the total amount of therapeutic material that can be delivered once the device is implanted.
  • a method of the invention includes loading a structure comprising a porous material with a heavy metal water-soluble salt dispersed throughout a substantial portion of the porous material, sterilizing the loaded structure, and packaging for storage and, optionally, delivery of the sterilized loaded structure.
  • the method of the invention further includes substantially contemporaneously loading of a water-soluble therapeutic material, wherein a water insoluble salt of the therapeutic material is produced throughout a substantial portion of the porous material of the structure.
  • “Substantially contemporaneously,” means that the step of loading a water soluble therapeutic material occurs at or near a step of positioning the device proximate to a desired area, i.e., at or near the surgical arena prior to administration to or implantation in, a patient. More preferably, the water insoluble salt of the therapeutic material is dispersed throughout a substantial portion of the porous material.
  • a method in another aspect of the invention, includes loading a structure comprising a porous material with a heavy metal water-soluble salt dispersed throughout a substantial portion of the porous material; loading a water soluble therapeutic material, wherein a water insoluble salt of the therapeutic material is produced in a substantial portion of the porous material of the structure; and packaging for delivery of the loaded structure.
  • the methods for making an implantable device to deliver a therapeutic material and device in vivo, or in an extracorporeal circuit in accordance with the invention are versatile.
  • a therapeutic material may be loaded onto a structure including a porous material at any number of points between, and including, the point of manufacture and the point of use.
  • the device can be stored and transported prior to incorporation of the therapeutic material.
  • the end user can select the therapeutic material to be used from a wider range of therapeutic agents.
  • FIG. 1 is an elevational view of one embodiment of a device according to the invention with a balloon catheter as a mode of delivery of the device;
  • FIG. 2 is an elevational view of another embodiment of a device according to the invention with a balloon catheter as a mode of delivery of the device;
  • FIG. 3 is a flow diagram schematically illustrating methods according to the invention.
  • FIG. 4 is a photograph taken from a scanning electron microscope of a surface showing the insoluble therapeutic material according to the invention.
  • FIGS. 5 a and 5 b are photographs showing the histological comparison between a stent heparinized according to the present invention ( 5 a ) and a control stent ( 5 b ).
  • a stent for use in artery/vascular therapies.
  • the term “stent” refers to any device capable of being delivered by a catheter and which, when placed into contact with a portion of a wall of a lumen to be treated, will also deliver localized therapeutic material at a luminal or blood-contacting portion of the device.
  • a stent typically includes a lumen wall-contacting surface and a lumen-exposed surface. Where the stent is shaped generally cylindrical or tube-like, including a discontinuous tube or ring-like structure, the lumen-wall contacting surface is the surface in close proximity to the lumen wall whereas the lumen exposed surface is the inner surface of the cylindrical stent.
  • the stent can include polymeric or metallic elements, or combinations thereof, onto which a porous material is applied.
  • a deformable metal wire stent is useful as a stent framework of this invention, such as that described in U.S. Pat. No. 4,886,062 to Wiktor, which discloses preferred methods for making a wire stent.
  • Other metallic stents useful in this invention include those of U.S. Pat. No. 4,733,655 to Palmaz and U.S. Pat. No. 4,800,882 to Gianturco.
  • the stent 20 comprises a stent framework 22 and a porous material coating 24 .
  • the stent framework 22 is deformable and can be formed from a polymeric material, a metal or a combination thereof.
  • a balloon 16 is positioned in FIG. 1 adjacent the lumen-exposed surface of the stent to facilitate delivery of the stent.
  • the stent 20 can be modified to increase or to decrease the number of wires provided per centimeter in the stent framework 22 . Similarly, the number of wire turns per centimeter can also be modified to produce a stiffer or a more flexible stent framework.
  • Polymeric stents can also be used in this invention.
  • the polymers can be nonbioabsorbable or bioabsorbable in part, or total.
  • Stents of this invention can be completely nonbioabsorbable, totally bioabsorbable or a composite of bioabsorbable polymer and nonabsorbable metal or polymer.
  • another stent suitable for this invention includes the self-expanding stent of resilient polymeric material as disclosed in International Publication No. WO 91/12779.
  • Nonbioabsorbable polymers can be used as alternatives to metallic stents.
  • the stents of this invention should not substantially induce inflammatory and neointimal responses.
  • biostable nonabsorbable polymers that have been used for stent construction with or without metallic elements include polyethylene terephthalate (PET), polyurethane urea and silicone (for example, see van Beusekom et al. Circulation 86(supp. 1):I-731, 1992 and Lincoff et al. J Am. Call Cardial . 21(supp. 1):335A, 1994.
  • the porous material is shown as a coating 24 , it is to be understood that, for the purposes of this invention, the porous material can be incorporated into the material of the stent.
  • an alternative stent 30 is shown.
  • the stent framework 34 is affixed with a film of a porous material 32 .
  • the film 32 is preferably wrapped over the framework with folds or wrinkles that will allow the stent 30 to be readily expanded into contact with the wall of the lumen to be treated.
  • the film 32 is located on a lumen-wall contacting surface 33 of the stent framework 34 such that radiation is substantially locally delivered to a lumen wall, for example, an arterial wall membrane (not shown).
  • the device according to the invention is generally a structure including a porous material.
  • the porous material is a film on at least a portion of the structure.
  • the porous material is an integral portion of the structure.
  • the porous material is biocompatible, and sufficiently tear-resistant and nonthrombogenic.
  • the porous material is selected from the group of a natural hydrogel, a synthetic hydrogel, teflon, silicone, polyurethane, polysulfone, cellulose, polyethylene, polypropylene, polyamide, polyester, polytetrafluoroethylene, and a combination of two or more of these materials.
  • natural hydrogels include fibrin, collagen, elastin, and the like.
  • pores between one micrometer in diameter or as large as 1000 micrometers in diameter can be introduced by conventional means such as by introducing a solvent soluble particulate material into the desired structure and dissolving the particulate material with a solvent.
  • a solvent soluble particulate material into the desired structure and dissolving the particulate material with a solvent.
  • no particular pore size is critical to this invention.
  • the therapeutic material used in the present invention could be virtually any therapeutic substance which possesses desirable therapeutic characteristics and which can be provided in both water soluble and water insoluble salts and which have bioactivity as an insoluble salt.
  • antithrombotics, antiplatelet agents, antimitotic agents, antioxidants, antimetabolite agents, anti-inflammatory agents and radioisotopes could be used.
  • “Insoluble salt” or “water insoluble salt” of the therapeutic substance as set forth herein means that the salt formed has a relatively poor solubility in water such that it will not readily disperse from the pores of the device.
  • anticoagulant agents such as heparin, heparin derivatives and heparin analogs could be used to prevent the formation of blood clots on the device.
  • water-insoluble radioactive salts such as AgI 125 , BaS 35 O 4 ,and (Ca) 3 (p 32 O 4 ) 2 could be used for application of radiotherapy to a body lumen or blood.
  • the water-insoluble salt of the therapeutic material is formed by a heavy metal water-soluble salt interacting with an aqueous radioactive salt solution.
  • the heavy metal water-soluble salt is dispersed throughout a substantial portion of the porous material.
  • the heavy metal water-soluble salt is selected from the group of AgNO 3 , Ba(NO 3 ) 2 , BaCl 2 , CaCI 2 , and a mixture thereof. The amount of water-soluble salt dispersed throughout a portion of the porous material determines the ultimate amount of therapeutic material capable of being administered once the device is implanted.
  • a structure having a porous material is loaded with a heavy metal water-soluble salt.
  • this step includes contacting, more preferably immersing, the structure with an aqueous solution of the heavy metal water-soluble salt, as described above.
  • the heavy metal water-soluble salt is dispersed throughout a substantial portion of the porous material. This may be assisted by degassing the pores of the structure by such techniques as ultrasound or vacuum degassing.
  • the resulting structure can now be sterilized, packaged and, optionally, stored until use.
  • a sterilized structure is shipped or delivered to the relevant consumer.
  • the structure is substantially contemporaneously loaded with a water soluble therapeutic material.
  • the loading of the therapeutic material includes contacting, more preferably immersing, the porous material in an aqueous solution comprising a salt of the therapeutic material, as described above.
  • degassing of the device can help to bring the therapeutic material into the pores.
  • a water-insoluble therapeutic salt is thereby formed within the porous material.
  • aqueous radioactive salt solutions for radiotherapy include Nal 125 K 2 S 35 O 4 , NaS 35 O 4 , an Na 3 P 32 O 4 , to name a few.
  • This method is advantageous in that the structure can be loaded with the therapeutic material in situ, i.e., at or near the point of therapeutic use, typically before administration, preferably implantation, to a patient.
  • This is particularly useful because the device can be stored and transported prior to incorporation of the therapeutic material.
  • This feature has several advantages. For example, the relevant consumer can select the therapeutic material to be used from a wider range of therapeutic materials, e.g., a radioisotope with a certain half-life with certain particle emitting characteristics can be selected.
  • the therapeutic material selected is not limited to only those supplied with the device but can instead be applied according to the therapy required.
  • a sterilized structure is loaded with a therapeutic material.
  • the loading of the therapeutic material includes contacting, more preferably immersing, the porous material in an aqueous solution comprising a salt of the therapeutic material, wherein a water-insoluble salt of the therapeutic material is formed within the porous material.
  • therapeutic salt solutions may be those previously mentioned above.
  • the structure is preferably packaged and can shipped to the relevant consumer.
  • the structure can now be administered, preferably implanted, to a patient.
  • the structure is loaded with the therapeutic material prior to reaching the point of use, which may be more convenient depending upon the facilities available to the relevant consumer.
  • Solution A 1-10% aqueous solution of BaCl 2
  • Solution B 1-10% aqueous solution of Ba(NO 3 ) 2
  • Solution C 1-10% aqueous solution of Na 2 S 35 O 4
  • a gamma-radiation sterilized porcine fibrin stent made according to U.S. Pat. No. 5,510,077 was treated by rehydration in Solution A by immersion for about 5 to about 10 minutes, the stent was removed and excess solution was blotted with absorbent paper. The stent was then dehydrated and sterilized by gamma radiation.
  • This treated stent was then rehydrated in an aqueous solution of Na 2 S 35 O 4 radioisotope having a specific activity of about 10 ⁇ Ci/ml to about 500 ⁇ Ci/ml. A white precipitate of BaS 35 O 4 was observed within the pores of the stent surface.
  • the stent can now be implanted into an artery for localized delivery of ⁇ -radiation or packaged for delivery to the consumer.
  • Fibrin stents made according to U.S. Pat. No. 5,510,077 were soaked in a 20% by weight solution of BaCl 2 (preferably soaking for about 10 to 30 minutes). The stents were then subjected to degassing by vacuum to remove air from the pores of the fibrin matrix, thus allowing the BaCl 2 solution to fill the pores. The stents were dried overnight.
  • the dried stents were placed into a solution of sodium heparinate (preferably soaking in a solution of 1000 U/ml to 20,000 U/ml for 10-20 minutes—most preferably a solution of at least 10,000 U/ml) to allow the BaCl 2 in the fibrin matrix to react with the sodium heparinate to form barium heparinate which was precipitated within the fibrin matrix.
  • Scanning electron microscopy (SEM) showed that particulates of barium heparinate in the order of 10 microns and smaller were trapped within the fibrin matrix (FIG. 4).
  • SEM scanning electron microscopy
  • the stents were compared for flow and were then examined histologically. While flow did not differ in a statistically significant manner between the control stent and the barium heparinate stent, the histological study showed substantially reduced clot formation on the barium heparinate stent (FIG. 5 a ) when compared with the control stent (FIG. 5 b ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A device useful for localized delivery of a therapeutic material is provided. The device includes a structure including a porous material; and a water-insoluble salt of a therapeutic material dispersed in the porous material. The water-insoluble salt is formed by contacting an aqueous solution of a therapeutic salt with a heavy metal water-soluble salt dispersed throughout a substantial portion of the porous material. The heavy metal water-soluble salt can be dispersed in the porous material so that the device can be sterilized and the therapeutic material can be loaded in the device in situ, for example, just prior to use. The therapeutic material is preferably a heparin or heparin derivative or analog which renders the material antithrombotic as an implantable or invasive device.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 09/769,423, filed Jan. 26, 2001, which is a continuation of U.S. application Ser. No. 08/877,532, filed Jun. 17, 1997, that issued as U.S. Pat. No. 6,203,536, the disclosures of each of which are hereby incorporated by reference herein in their entireties.[0001]
    • BACKGROUND OF THE INVENTION
  • This invention relates to a medical device employing a therapeutic substance as a component thereof. For example in an arterial site treated with percutaneous transluminal coronary angioplasty therapy for obstructive coronary artery disease a therapeutic antithrombogenic substance such as heparin may be included with a device and delivered locally in the coronary artery. Also provided is a method for making a medical device capable of localized application of therapeutic substances. [0002]
  • Medical devices which serve as substitute blood vessels, synthetic and intraocular lenses, electrodes, catheters and the like in and on the body or as extracorporeal devices intended to be connected to the body to assist in surgery or dialysis are well known. For example, intravascular procedures can bring medical devices into contact with the patient's vasculature. In treating a narrowing or constriction of a duct or canal percutaneous transluminal coronary angioplasty (PTCA) is often used with the insertion and inflation of a balloon catheter into a stenotic vessel. Other intravascular invasive therapies include atherectomy (mechanical systems to remove plaque residing inside an artery), laser ablative therapy and the like. However, this use of mechanical repairs can have adverse consequences for the patient. For example, restenosis at the site of a prior invasive coronary artery disease therapy occurs in a majority of cases. Restenosis, defined angiograhpically, is the recurrence of a 50% or greater narrowing of a luminal diameter at the site of a prior coronary artery disease therapy, such as a balloon dilatation in the case of PTCA therapy. In particular, an intra-luminal component of restenosis develops near the end of the healing process initiated by vascular injury, which then contributes to the narrowing of the luminal diameter. This phenomenon is sometimes referred to as “intimal hyperplasia.” It is believed that a variety of biologic factors are involved in restenosis, such as the extent of the injury, platelets, inflammatory cells, growth factors, cytokines, endothelial cells, smooth muscle cells, and extracellular matrix production, to name a few. [0003]
  • Attempts to inhibit or diminish restenosis often include additional interventions such as the use of intravascular stents and the intravascular administration of pharmacological therapeutic agents. Examples of stents which have been successfully applied over a PTCA balloon and radially expanded at the same time as the balloon expansion of an affected artery include the stents disclosed in U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat.No. 4,800,882 issued to Gianturco and U.S. Pat. No. 4,886,062 issued to Wiktor. Also, such stents employing therapeutic substances such as glucocorticoids (e.g. dexamethasone, betamethasone), heparin, hirudin, tocopherol, angiopeptin, aspirin, ACE inhibitors, growth factors, oligonucleotides, and, more generally, antiplatelet agents, anticoagulant agents, antimitotic agents, antioxidants, antimetabolite agents, and anti-inflammatory agents have been considered for their potential to solve the problem of restenosis. [0004]
  • Another concern with intravascular and extracorporeal procedures is the contact of biomaterials with blood which can trigger the body's hemostatic process. The hemostatic process is normally initiated as the body's response to injury. When a vessel wall is injured, platelets adhere to damaged endothelium or exposed subendothelium. Following adhesion of the platelets, these cells cohere to each other preparatory to aggregation and secretion of their intracellular contents. Simultaneously there is activation, probably by electrostatic charge of the contact factors, of the coagulation cascade. The sequential step-wise interaction of these procoagulant proteins results in the transformation of soluble glycoproteins into insoluble polymers, which after transamidation results in the irreversible solid thrombus. [0005]
  • Immobilization of polysaccharides such as heparin to biomaterials has been used to improve bio- and hemocompatibility of implantable and extracorporeal devices. The mechanism responsible for reduced thrombogenicity of heparinized materials is believed to reside in the ability of heparin to speed up the inactivation of serine proteases (blood coagulation enzymes) by AT-Ill. In the process, AT-III forms a complex with a well defined pentasaccharide sequence in heparin, undergoing a conformational change and thus enhancing the ability of AT-III to form a covalent bond with the active sites of serine proteases such as thrombin. The formed TAT-complex then releases from the polysaccharide, leaving the heparin molecule behind for a second round of inactivation. [0006]
  • Usually, immobilization of heparin to a biomaterial surface consists of activating the material in such away that coupling between the biomaterial and finctional groups on the heparin (—COOH, —OH, —NH[0007] 2) can be achieved. For example, Larm presented (in U.S. Pat. No. 4,613,665) a method to activate heparin via a controlled nitrous acid degradation step, resulting in degraded heparin molecules of which a part contains a free terminal aldehyde group. Heparin in this form can be covalently bound to an aminated surface in a reductive animation process. Although the molecule is degraded and as a result shows less catalytic activity in solution, the end point attachment of this type of heparin to a surface results in true anti-thromogenicity due to the proper presentation of the biomolecule to the surface. In this fashion, the molecule is freely interacting with AT-III and the coagulation enzymes, preventing the generation of thrombi and microemboli.
  • However, the attachment and delivery of therapeutic substances such as heparin can involve complicated and expensive chemistry. It is therefore an object of the present invention to provide a medical device having a biocompatible, blood-contacting surface with an active therapeutic substance at the surface and a simple, inexpensive method for producing such a surface. [0008]
    • SUMMARY OF THE INVENTION
  • This invention relates to a medical device having a blood-contacting surface with a therapeutic substance thereon. Preferably, the device according to the invention is capable of applying a highly localized therapeutic material into a body lumen to treat or prevent injury. The term “injury” means a trauma, that may be incidental to surgery or other treatment methods including deployment of a stent, or a biologic disease, such as an immune response or cell proliferation caused by the administration of growth factors. In addition, the methods of the invention may be performed in anticipation of “injury” as a prophylactic. A prophylactic treatment is one that is provided in advance of any symptom of injury in order to prevent injury, prevent progression of injury or attenuate any subsequent onset of a symptom of such injury. [0009]
  • In accordance with the invention, a device for delivery of localized therapeutic material includes a structure including a porous material and a plurality of discrete particles of a water-insoluble salt of the therapeutic material dispersed throughout a substantial portion of the porous material. Preferably, the device is capable of being implanted in a body so that the localized therapeutic agent can be delivered in vivo, typically at a site of vascular injury or trauma. More preferably, the porous material is also biocompatible, sufficiently tear resistant and nonthrombogenic. [0010]
  • The porous material may be a film on at least a portion of the structure or the porous material may be an integral portion of the structure. Preferably, the porous material is selected from the group of a natural hydrogel, a synthetic hydrogel, teflon, silicone, polyurethane, polysulfone, cellulose, polyethylene, polypropylene, polyamide, polyester, polytetrafluoroethylene, and a combination of two or more of these materials. Examples of natural hydrogels include fibrin, collagen, elastin, and the like. [0011]
  • The therapeutic agent preferably includes an antithrombotic material. More preferably, the antithrombotic material is a heparin or heparin derivative or analog. Also preferably, the insoluble salt of the therapeutic material is one of the silver, barium or calcium salts of the material. [0012]
  • The structure of the device can be adapted for its intended extracorporeal or intravascular purpose in an internal human body site, such as an artery, vein, urethra, other body lumens, cavities, and the like or in an extracorporeal blood pump, blood filter, blood oxygenator or tubing. In one aspect of the invention, the shape is preferably generally cylindrical, and more preferably, the shape is that of a catheter, a stent, or a guide wire. [0013]
  • In another aspect of the invention, an implantable device capable of delivery of a therapeutic material includes a structure comprising a porous material; and a plurality of discrete particles comprising a heavy metal water soluble salt dispersed throughout a substantial portion of the porous material. Preferably, the heavy metal water-soluble salt is selected from the group of AgNO[0014] 3, Ba(NO3)2, BaCl2, and CaCl2. The amount of water-soluble salt dispersed throughout a portion of the porous material determines the total amount of therapeutic material that can be delivered once the device is implanted.
  • The invention also provides methods for making an implantable device which includes therapeutic materials. In one embodiment, a method of the invention includes loading a structure comprising a porous material with a heavy metal water-soluble salt dispersed throughout a substantial portion of the porous material, sterilizing the loaded structure, and packaging for storage and, optionally, delivery of the sterilized loaded structure. Preferably, the method of the invention further includes substantially contemporaneously loading of a water-soluble therapeutic material, wherein a water insoluble salt of the therapeutic material is produced throughout a substantial portion of the porous material of the structure. “Substantially contemporaneously,” means that the step of loading a water soluble therapeutic material occurs at or near a step of positioning the device proximate to a desired area, i.e., at or near the surgical arena prior to administration to or implantation in, a patient. More preferably, the water insoluble salt of the therapeutic material is dispersed throughout a substantial portion of the porous material. [0015]
  • In another aspect of the invention, a method includes loading a structure comprising a porous material with a heavy metal water-soluble salt dispersed throughout a substantial portion of the porous material; loading a water soluble therapeutic material, wherein a water insoluble salt of the therapeutic material is produced in a substantial portion of the porous material of the structure; and packaging for delivery of the loaded structure. [0016]
  • Thus, the methods for making an implantable device to deliver a therapeutic material and device in vivo, or in an extracorporeal circuit in accordance with the invention, are versatile. A therapeutic material may be loaded onto a structure including a porous material at any number of points between, and including, the point of manufacture and the point of use. As a result of one method, the device can be stored and transported prior to incorporation of the therapeutic material. Thus, the end user can select the therapeutic material to be used from a wider range of therapeutic agents.[0017]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is an elevational view of one embodiment of a device according to the invention with a balloon catheter as a mode of delivery of the device; [0018]
  • FIG. 2 is an elevational view of another embodiment of a device according to the invention with a balloon catheter as a mode of delivery of the device; and [0019]
  • FIG. 3 is a flow diagram schematically illustrating methods according to the invention. [0020]
  • FIG. 4 is a photograph taken from a scanning electron microscope of a surface showing the insoluble therapeutic material according to the invention. [0021]
  • FIGS. 5[0022] a and 5 b are photographs showing the histological comparison between a stent heparinized according to the present invention (5 a) and a control stent (5 b).
    • DESCRIPTION OF PREFERRED EMBODIMENTS
  • One of the more preferred configurations for a device according to the invention is a stent for use in artery/vascular therapies. The term “stent” refers to any device capable of being delivered by a catheter and which, when placed into contact with a portion of a wall of a lumen to be treated, will also deliver localized therapeutic material at a luminal or blood-contacting portion of the device. A stent typically includes a lumen wall-contacting surface and a lumen-exposed surface. Where the stent is shaped generally cylindrical or tube-like, including a discontinuous tube or ring-like structure, the lumen-wall contacting surface is the surface in close proximity to the lumen wall whereas the lumen exposed surface is the inner surface of the cylindrical stent. The stent can include polymeric or metallic elements, or combinations thereof, onto which a porous material is applied. For example, a deformable metal wire stent is useful as a stent framework of this invention, such as that described in U.S. Pat. No. 4,886,062 to Wiktor, which discloses preferred methods for making a wire stent. Other metallic stents useful in this invention include those of U.S. Pat. No. 4,733,655 to Palmaz and U.S. Pat. No. 4,800,882 to Gianturco. [0023]
  • Referring now to FIG. 1, the [0024] stent 20 comprises a stent framework 22 and a porous material coating 24. The stent framework 22 is deformable and can be formed from a polymeric material, a metal or a combination thereof. A balloon 16 is positioned in FIG. 1 adjacent the lumen-exposed surface of the stent to facilitate delivery of the stent. The stent 20 can be modified to increase or to decrease the number of wires provided per centimeter in the stent framework 22. Similarly, the number of wire turns per centimeter can also be modified to produce a stiffer or a more flexible stent framework.
  • Polymeric stents can also be used in this invention. The polymers can be nonbioabsorbable or bioabsorbable in part, or total. Stents of this invention can be completely nonbioabsorbable, totally bioabsorbable or a composite of bioabsorbable polymer and nonabsorbable metal or polymer. For example, another stent suitable for this invention includes the self-expanding stent of resilient polymeric material as disclosed in International Publication No. WO 91/12779. [0025]
  • Nonbioabsorbable polymers can be used as alternatives to metallic stents. The stents of this invention should not substantially induce inflammatory and neointimal responses. Examples of biostable nonabsorbable polymers that have been used for stent construction with or without metallic elements include polyethylene terephthalate (PET), polyurethane urea and silicone (for example, see van Beusekom et al. [0026] Circulation 86(supp. 1):I-731, 1992 and Lincoff et al. J Am. Call Cardial. 21(supp. 1):335A, 1994. Although the porous material is shown as a coating 24, it is to be understood that, for the purposes of this invention, the porous material can be incorporated into the material of the stent.
  • Referring to FIG. 2, an [0027] alternative stent 30 is shown. The stent framework 34 is affixed with a film of a porous material 32. This can be accomplished by wrapping the film 32 around the stent framework 34 and securing the film 32 to the framework 34 (i.e., the film is usually sufficiently tacky to adhere itself to the framework but a medical grade adhesive could also be used if needed) so that the film 32 will stay on the balloon 36 and framework 34 until it is delivered to the site of treatment. The film 32 is preferably wrapped over the framework with folds or wrinkles that will allow the stent 30 to be readily expanded into contact with the wall of the lumen to be treated. Preferably, the film 32 is located on a lumen-wall contacting surface 33 of the stent framework 34 such that radiation is substantially locally delivered to a lumen wall, for example, an arterial wall membrane (not shown).
  • Porous Material [0028]
  • As mentioned above, the device according to the invention is generally a structure including a porous material. In one embodiment, the porous material is a film on at least a portion of the structure. In another embodiment, the porous material is an integral portion of the structure. Preferably, the porous material is biocompatible, and sufficiently tear-resistant and nonthrombogenic. More preferably, the porous material is selected from the group of a natural hydrogel, a synthetic hydrogel, teflon, silicone, polyurethane, polysulfone, cellulose, polyethylene, polypropylene, polyamide, polyester, polytetrafluoroethylene, and a combination of two or more of these materials. Examples of natural hydrogels include fibrin, collagen, elastin, and the like. In materials which do not include pores in their usual structural configurations, pores between one micrometer in diameter or as large as 1000 micrometers in diameter can be introduced by conventional means such as by introducing a solvent soluble particulate material into the desired structure and dissolving the particulate material with a solvent. However, no particular pore size is critical to this invention. [0029]
  • Therapeutic Material [0030]
  • The therapeutic material used in the present invention could be virtually any therapeutic substance which possesses desirable therapeutic characteristics and which can be provided in both water soluble and water insoluble salts and which have bioactivity as an insoluble salt. For example, antithrombotics, antiplatelet agents, antimitotic agents, antioxidants, antimetabolite agents, anti-inflammatory agents and radioisotopes could be used. “Insoluble salt” or “water insoluble salt” of the therapeutic substance as set forth herein, means that the salt formed has a relatively poor solubility in water such that it will not readily disperse from the pores of the device. In particular, anticoagulant agents such as heparin, heparin derivatives and heparin analogs could be used to prevent the formation of blood clots on the device. Also, water-insoluble radioactive salts such as AgI[0031] 125, BaS35O4,and (Ca)3(p32O4)2 could be used for application of radiotherapy to a body lumen or blood.
  • Preferably, the water-insoluble salt of the therapeutic material is formed by a heavy metal water-soluble salt interacting with an aqueous radioactive salt solution. In the present invention, the heavy metal water-soluble salt is dispersed throughout a substantial portion of the porous material. Preferably, the heavy metal water-soluble salt is selected from the group of AgNO[0032] 3, Ba(NO3)2, BaCl2, CaCI2, and a mixture thereof. The amount of water-soluble salt dispersed throughout a portion of the porous material determines the ultimate amount of therapeutic material capable of being administered once the device is implanted.
  • Methods of Making an Implantable Device [0033]
  • Referring now to FIG. 3, a structure having a porous material is loaded with a heavy metal water-soluble salt. Preferably, this step includes contacting, more preferably immersing, the structure with an aqueous solution of the heavy metal water-soluble salt, as described above. Preferably, the heavy metal water-soluble salt is dispersed throughout a substantial portion of the porous material. This may be assisted by degassing the pores of the structure by such techniques as ultrasound or vacuum degassing. The resulting structure can now be sterilized, packaged and, optionally, stored until use. [0034]
  • In one embodiment of the invention, a sterilized structure is shipped or delivered to the relevant consumer. The structure is substantially contemporaneously loaded with a water soluble therapeutic material. Preferably, the loading of the therapeutic material includes contacting, more preferably immersing, the porous material in an aqueous solution comprising a salt of the therapeutic material, as described above. Again, degassing of the device can help to bring the therapeutic material into the pores. A water-insoluble therapeutic salt is thereby formed within the porous material. Examples of aqueous radioactive salt solutions for radiotherapy include Nal[0035] 125 K2S35O4, NaS35O4, an Na3P32O4, to name a few.
  • This method is advantageous in that the structure can be loaded with the therapeutic material in situ, i.e., at or near the point of therapeutic use, typically before administration, preferably implantation, to a patient. This is particularly useful because the device can be stored and transported prior to incorporation of the therapeutic material. This feature has several advantages. For example, the relevant consumer can select the therapeutic material to be used from a wider range of therapeutic materials, e.g., a radioisotope with a certain half-life with certain particle emitting characteristics can be selected. Thus, the therapeutic material selected is not limited to only those supplied with the device but can instead be applied according to the therapy required. [0036]
  • In another aspect of the invention, a sterilized structure is loaded with a therapeutic material. Preferably, the loading of the therapeutic material includes contacting, more preferably immersing, the porous material in an aqueous solution comprising a salt of the therapeutic material, wherein a water-insoluble salt of the therapeutic material is formed within the porous material. Examples of therapeutic salt solutions may be those previously mentioned above. The structure is preferably packaged and can shipped to the relevant consumer. The structure can now be administered, preferably implanted, to a patient. Thus, in this embodiment, the structure is loaded with the therapeutic material prior to reaching the point of use, which may be more convenient depending upon the facilities available to the relevant consumer. [0037]
  • The following non-limiting examples will further illustrate the invention. All parts, percentages, ratios, etc. are by weight unless otherwise indicated. [0038]
    • EXAMPLE 1
  • The following solutions were used in the procedure: [0039]
  • Solution A: 1-10% aqueous solution of BaCl[0040] 2
  • Solution B: 1-10% aqueous solution of Ba(NO[0041] 3)2
  • Solution C: 1-10% aqueous solution of Na[0042] 2S35O4
  • A gamma-radiation sterilized porcine fibrin stent made according to U.S. Pat. No. 5,510,077 was treated by rehydration in Solution A by immersion for about 5 to about 10 minutes, the stent was removed and excess solution was blotted with absorbent paper. The stent was then dehydrated and sterilized by gamma radiation. [0043]
  • This treated stent was then rehydrated in an aqueous solution of Na[0044] 2S35O4 radioisotope having a specific activity of about 10 μCi/ml to about 500 μCi/ml. A white precipitate of BaS35O4 was observed within the pores of the stent surface. The stent can now be implanted into an artery for localized delivery of β-radiation or packaged for delivery to the consumer.
    • EXAMPLE 2
  • Fibrin stents made according to U.S. Pat. No. 5,510,077 were soaked in a 20% by weight solution of BaCl[0045] 2 (preferably soaking for about 10 to 30 minutes). The stents were then subjected to degassing by vacuum to remove air from the pores of the fibrin matrix, thus allowing the BaCl2 solution to fill the pores. The stents were dried overnight. The dried stents were placed into a solution of sodium heparinate (preferably soaking in a solution of 1000 U/ml to 20,000 U/ml for 10-20 minutes—most preferably a solution of at least 10,000 U/ml) to allow the BaCl2 in the fibrin matrix to react with the sodium heparinate to form barium heparinate which was precipitated within the fibrin matrix. Scanning electron microscopy (SEM) showed that particulates of barium heparinate in the order of 10 microns and smaller were trapped within the fibrin matrix (FIG. 4). In vivo evaluation of the barium heparinate stents were carried out using a carotid crush model in pigs with standard fibrin stents as controls. After 24 hours, the stents were compared for flow and were then examined histologically. While flow did not differ in a statistically significant manner between the control stent and the barium heparinate stent, the histological study showed substantially reduced clot formation on the barium heparinate stent (FIG. 5a) when compared with the control stent (FIG. 5b).
  • The complete disclosures of all patents, patent applications, and publications referenced herein are incorporated herein by reference as if individually incorporated. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to illustrative embodiments set forth herein. [0046]

Claims (39)

We claim:
1. A system for use in the prevention or treatment of an arterial injury comprising: a drug eluting stent and a delivery catheter, wherein said drug eluting stent comprises:
a) a stent framework; and
b) a porous material having a consistently distributed porosity with a plurality of particles of a water-insoluble salt of a therapeutic material dispersed throughout said porous material.
2. The system of claim 1, wherein said stent framework is a metallic material.
3. The system of claim 1, wherein said stent framework is a polymeric material.
4. The system of claim 1, wherein said stent framework is selected so as to allow said stent to be self-expanding.
5. The system of claim 1, wherein said stent framework is a combination of metallic and polymeric elements.
6. The system of claim 3, wherein said polymeric material is nonbioadsorbable.
7. The system of claim 3, wherein said polymeric material is bioadsorbable.
8. The system of claim 3, wherein said polymeric material is a composite of bioadsorbable and nonbioadsorbable polymeric materials.
9. The system of claim 1, wherein said stent framework is a composite of bioadsorbable and nonbioadsorbable elements.
10. The system of claim 9, wherein said bioadsorbable element is a polymeric material and said nonbioadsorbable element is a metallic material.
11. The system of claim 6, wherein said nonbioadsorbable polymeric material is selected from the group consisting of polyethylene terephthalate, polyurethane urea and silicone.
12. The system of claim 8, wherein said nonbioadsorbable polymeric material is selected from the group consisting of polyethylene terephthalate, polyurethane urea and silicone.
13. The system of claim 1, wherein said porous material is a film disposed on the outer surface of said stent framework.
14. The system of claim 13, wherein said film is selected from the group consisting of TEFLON, silicone, polyurethane, polysulfone, polyethylene, polypropylene, polyamide, polyester, polytetrafluoroethylene, and a combination of two or more of these materials.
15. The system of claim 13, wherein said film is selected from the group consisting of a natural hydrogel, a synthetic hydrogel, and cellulose, and a combination of two or more of these materials.
16. The system of claim 1, wherein said porous material is incorporated into said stent framework.
17. The system of claim 16, wherein said porous material is selected from the group consisting of TEFLON, silicone, polyurethane, polysulfone, polyethylene, polypropylene, polyamide, polyester, polytetrafluoroethylene, and a combination of two or more of these materials.
18. The system of claim 16, wherein said porous material is selected from the group consisting of a natural hydrogel, a synthetic hydrogel, and cellulose, and a combination of two or more of these materials.
19. The system of claim 1, wherein said water-insoluble salt of a therapeutic material comprises an antithrombotic material.
20. The system of claim 19, wherein said antithrombotic material is heparin.
21. The system of claim 1, wherein said water-insoluble salt of said therapeutic material is selected from the group consisting of barium, and calcium salts of said therapeutic material.
22. The system of claim 1, wherein said therapeutic material comprises at least one substance selected from the group consisting of an antithrombotic, an antiplatelet agent, an anticoagulant agent, an antimitotic agent, an antioxidant agent, an antimetabolite agent, and an anti-inflammatory agent.
23. The system of claim 1, wherein said therapeutic material is effective to treat or prevent restenosis.
24. The system of claim 1, wherein said water-insoluble salt of a therapeutic material is a radioactive salt.
25. A system for use in the prevention or treatment of an arterial injury comprising: a drug eluting stent and a delivery catheter, wherein said drug eluting stent comprises:
a) a stent framework; and
b) a porous material having a consistently distributed porosity with a plurality of particles of a water-insoluble salt of a therapeutic material dispersed throughout said porous material,
wherein said stent framework is a composite of at least one bioadsorbable polymeric material and at least one nonbioadsorbable polymeric material.
26. The system of claim 25, wherein said polymeric materials are selected so as to allow said stent to be self-expanding.
27. The system of claim 25, wherein said nonbioadsorbable polymeric material is selected from the group consisting of polyethylene terephthalate, polyurethane urea and silicone.
28. The system of claim 25, wherein said porous material is a film disposed on the outer surface of said stent framework.
29. The system of claim 28, wherein said film is selected from the group consisting of TEFLON, silicone, polyurethane, polysulfone, polyethylene, polypropylene, polyamide, polyester, polytetrafluoroethylene, and a combination of two or more of these materials.
30. The system of claim 28, wherein said film is selected from the group consisting of a natural hydrogel, a synthetic hydrogel, and cellulose, and a combination of two or more of these materials.
31. The system of claim 25, wherein said porous material is incorporated into said stent framework.
32. The system of claim 31, wherein said porous material is selected from the group consisting of TEFLON, silicone, polyurethane, polysulfone, polyethylene, polypropylene, polyamide, polyester, polytetrafluoroethylene, and a combination of two or more of these materials.
33. The system of claim 31, wherein said porous material is selected from the group consisting of a natural hydrogel, a synthetic hydrogel, and cellulose, and a combination of two or more of these materials.
34. The system of claim 25, wherein said water-insoluble salt of a therapeutic material comprises an antithrombotic material.
35. The system of claim 34, wherein said antithrombotic material is heparin.
36. The system of claim 25, wherein said water-insoluble salt of said therapeutic material is selected from the group consisting of barium, and calcium salts of said therapeutic material.
37. The system of claim 25, wherein said therapeutic material comprises at least one substance selected from the group consisting of an antithrombotic, an antiplatelet agent, an anticoagulant agent, an antimitotic agent, an antioxidant agent, an antimetabolite agent, and an anti-inflammatory agent.
38. The system of claim 25, wherein said therapeutic material is effective to treat or prevent restenosis.
39. The system of claim 25, wherein said water-insoluble salt of a therapeutic material is a radioactive salt.
US10/727,534 1997-06-17 2003-12-05 Medical device for delivering a therapeutic substance and method therefor Abandoned US20040111150A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/727,534 US20040111150A1 (en) 1997-06-17 2003-12-05 Medical device for delivering a therapeutic substance and method therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/877,532 US6203536B1 (en) 1997-06-17 1997-06-17 Medical device for delivering a therapeutic substance and method therefor
US09/769,423 US6730120B2 (en) 1997-06-17 2001-01-26 Medical device for delivering a therapeutic substance and method therefor
US10/727,534 US20040111150A1 (en) 1997-06-17 2003-12-05 Medical device for delivering a therapeutic substance and method therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/769,423 Continuation US6730120B2 (en) 1997-06-17 2001-01-26 Medical device for delivering a therapeutic substance and method therefor

Publications (1)

Publication Number Publication Date
US20040111150A1 true US20040111150A1 (en) 2004-06-10

Family

ID=25370170

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/877,532 Expired - Lifetime US6203536B1 (en) 1997-06-17 1997-06-17 Medical device for delivering a therapeutic substance and method therefor
US09/769,423 Expired - Fee Related US6730120B2 (en) 1997-06-17 2001-01-26 Medical device for delivering a therapeutic substance and method therefor
US10/727,534 Abandoned US20040111150A1 (en) 1997-06-17 2003-12-05 Medical device for delivering a therapeutic substance and method therefor

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/877,532 Expired - Lifetime US6203536B1 (en) 1997-06-17 1997-06-17 Medical device for delivering a therapeutic substance and method therefor
US09/769,423 Expired - Fee Related US6730120B2 (en) 1997-06-17 2001-01-26 Medical device for delivering a therapeutic substance and method therefor

Country Status (4)

Country Link
US (3) US6203536B1 (en)
EP (1) EP0920342B1 (en)
DE (1) DE69807634T2 (en)
WO (1) WO1998057680A2 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080268011A1 (en) * 2004-09-24 2008-10-30 Helmut Goldmann Antimicrobial Implant with a Flexible Porous Structure
US20090192079A1 (en) * 2007-10-09 2009-07-30 Genzyme Corporation Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020055710A1 (en) 1998-04-30 2002-05-09 Ronald J. Tuch Medical device for delivering a therapeutic agent and method of preparation
US6203536B1 (en) * 1997-06-17 2001-03-20 Medtronic, Inc. Medical device for delivering a therapeutic substance and method therefor
US6013099A (en) * 1998-04-29 2000-01-11 Medtronic, Inc. Medical device for delivering a water-insoluble therapeutic salt or substance
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US6770086B1 (en) * 2000-11-02 2004-08-03 Scimed Life Systems, Inc. Stent covering formed of porous polytetraflouroethylene
US9107605B2 (en) * 2000-11-17 2015-08-18 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Device for in vivo delivery of bioactive agents and method of manufacture thereof
US10398830B2 (en) * 2000-11-17 2019-09-03 Vactronix Scientific, Llc Device for in vivo delivery of bioactive agents and method of manufacture thereof
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US20050125054A1 (en) * 2000-12-22 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20030033007A1 (en) * 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US7018405B2 (en) 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
US6939375B2 (en) 2000-12-22 2005-09-06 Avantac Vascular Corporation Apparatus and methods for controlled substance delivery from implanted prostheses
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20020082678A1 (en) * 2000-12-22 2002-06-27 Motasim Sirhan Intravascular delivery of mizoribine
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20020082620A1 (en) * 2000-12-27 2002-06-27 Elaine Lee Bioactive materials for aneurysm repair
DE10118944B4 (en) 2001-04-18 2013-01-31 Merit Medical Systems, Inc. Removable, essentially cylindrical implants
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP4347044B2 (en) * 2001-07-26 2009-10-21 アバンテク バスキュラー コーポレーション Device for delivering a therapeutic agent having a variable release profile
DE60236093D1 (en) 2001-07-26 2010-06-02 Merit Medical Systems Inc REMOVABLE STENT
US20030181973A1 (en) * 2002-03-20 2003-09-25 Harvinder Sahota Reduced restenosis drug containing stents
JP3887588B2 (en) * 2002-08-30 2007-02-28 株式会社リガク Stress measurement method by X-ray diffraction
AU2003277023B2 (en) * 2002-09-26 2009-02-26 Endovascular Devices, Inc. Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device
US7959671B2 (en) 2002-11-05 2011-06-14 Merit Medical Systems, Inc. Differential covering and coating methods
US7527644B2 (en) 2002-11-05 2009-05-05 Alveolus Inc. Stent with geometry determinated functionality and method of making the same
US7875068B2 (en) 2002-11-05 2011-01-25 Merit Medical Systems, Inc. Removable biliary stent
US7637942B2 (en) 2002-11-05 2009-12-29 Merit Medical Systems, Inc. Coated stent with geometry determinated functionality and method of making the same
WO2004075944A2 (en) * 2003-02-26 2004-09-10 Coloplast A/S A medical device having a coating comprising hydrogen peroxide and package therefore
US20040236414A1 (en) * 2003-05-23 2004-11-25 Brar Balbir S. Devices and methods for treatment of stenotic regions
US7226473B2 (en) * 2003-05-23 2007-06-05 Brar Balbir S Treatment of stenotic regions
WO2005049105A2 (en) * 2003-11-10 2005-06-02 Angiotech International Ag Medical implants and anti-scarring agents
US7538096B2 (en) * 2004-03-16 2009-05-26 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
WO2005118016A1 (en) * 2004-05-27 2005-12-15 Medtronic, Inc. Medical device comprising a biologically active agent
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7887579B2 (en) * 2004-09-29 2011-02-15 Merit Medical Systems, Inc. Active stent
US7731654B2 (en) 2005-05-13 2010-06-08 Merit Medical Systems, Inc. Delivery device with viewing window and associated method
US8961586B2 (en) * 2005-05-24 2015-02-24 Inspiremd Ltd. Bifurcated stent assemblies
US8029558B2 (en) * 2006-07-07 2011-10-04 Abbott Cardiovascular Systems, Inc. Stent and catheter assembly and method for treating bifurcations
US9265866B2 (en) * 2006-08-01 2016-02-23 Abbott Cardiovascular Systems Inc. Composite polymeric and metallic stent with radiopacity
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
US20080119927A1 (en) * 2006-11-17 2008-05-22 Medtronic Vascular, Inc. Stent Coating Including Therapeutic Biodegradable Glass, and Method of Making
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
JP2008305262A (en) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc Printer introduction method in server and thin client environment
US8425591B1 (en) 2007-06-11 2013-04-23 Abbott Cardiovascular Systems Inc. Methods of forming polymer-bioceramic composite medical devices with bioceramic particles
US20090076591A1 (en) * 2007-09-19 2009-03-19 Boston Scientific Scimed, Inc. Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface
US7833266B2 (en) * 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US9101698B2 (en) * 2007-12-05 2015-08-11 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with radiopaque layer and method of fabrication
US7935143B2 (en) * 2008-01-02 2011-05-03 Abbott Cardiovascular Systems Inc. Stent formed from polymer-bioceramic composite with radiopaque bioceramic particles
AU2009267626A1 (en) * 2008-06-16 2010-01-14 Coloplast A/S Buffered swelling media for radiation sterilized hydrophilic coatings
US7951193B2 (en) * 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9839540B2 (en) 2011-01-14 2017-12-12 W. L. Gore & Associates, Inc. Stent
US10166128B2 (en) 2011-01-14 2019-01-01 W. L. Gore & Associates. Inc. Lattice
US9744033B2 (en) 2011-04-01 2017-08-29 W.L. Gore & Associates, Inc. Elastomeric leaflet for prosthetic heart valves
US9554806B2 (en) 2011-09-16 2017-01-31 W. L. Gore & Associates, Inc. Occlusive devices
US9510935B2 (en) 2012-01-16 2016-12-06 W. L. Gore & Associates, Inc. Articles including expanded polytetrafluoroethylene membranes with serpentine fibrils and having a discontinuous fluoropolymer layer thereon
US9283072B2 (en) 2012-07-25 2016-03-15 W. L. Gore & Associates, Inc. Everting transcatheter valve and methods
US10376360B2 (en) 2012-07-27 2019-08-13 W. L. Gore & Associates, Inc. Multi-frame prosthetic valve apparatus and methods
US10086110B2 (en) * 2012-10-30 2018-10-02 The Cleveland Clinic Foundation Multipurpose membranes, methods for forming, and applications thereof
US9931193B2 (en) 2012-11-13 2018-04-03 W. L. Gore & Associates, Inc. Elastic stent graft
US9144492B2 (en) 2012-12-19 2015-09-29 W. L. Gore & Associates, Inc. Truncated leaflet for prosthetic heart valves, preformed valve
US9101469B2 (en) 2012-12-19 2015-08-11 W. L. Gore & Associates, Inc. Prosthetic heart valve with leaflet shelving
US10279084B2 (en) 2012-12-19 2019-05-07 W. L. Gore & Associates, Inc. Medical balloon devices and methods
US10321986B2 (en) 2012-12-19 2019-06-18 W. L. Gore & Associates, Inc. Multi-frame prosthetic heart valve
US10966820B2 (en) 2012-12-19 2021-04-06 W. L. Gore & Associates, Inc. Geometric control of bending character in prosthetic heart valve leaflets
US9737398B2 (en) 2012-12-19 2017-08-22 W. L. Gore & Associates, Inc. Prosthetic valves, frames and leaflets and methods thereof
US9968443B2 (en) 2012-12-19 2018-05-15 W. L. Gore & Associates, Inc. Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet
US11911258B2 (en) 2013-06-26 2024-02-27 W. L. Gore & Associates, Inc. Space filling devices
US10842918B2 (en) 2013-12-05 2020-11-24 W.L. Gore & Associates, Inc. Length extensible implantable device and methods for making such devices
US9827094B2 (en) 2014-09-15 2017-11-28 W. L. Gore & Associates, Inc. Prosthetic heart valve with retention elements
KR102140862B1 (en) 2015-05-14 2020-08-03 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 Devices and methods for atrial occlusion
CA3021860C (en) 2016-04-21 2021-06-08 W. L. Gore & Associates, Inc. Diametrically adjustable endoprostheses and associated systems and methods
JP6974601B2 (en) 2017-09-12 2021-12-01 ダブリュ.エル.ゴア アンド アソシエイツ, インコーポレイティドW.L. Gore & Associates, Incorporated Leaflet frame mounting device for artificial valves
CN111163728B (en) 2017-09-27 2022-04-29 W.L.戈尔及同仁股份有限公司 Prosthetic valve with mechanically coupled leaflets
WO2019067219A1 (en) 2017-09-27 2019-04-04 W. L. Gore & Associates, Inc. Prosthetic valve with expandable frame and associated systems and methods
AU2018348022B2 (en) 2017-10-09 2021-07-08 W. L. Gore & Associates, Inc. Matched stent cover
US11090153B2 (en) 2017-10-13 2021-08-17 W. L. Gore & Associates, Inc. Telescoping prosthetic valve and delivery system
US11173023B2 (en) 2017-10-16 2021-11-16 W. L. Gore & Associates, Inc. Medical devices and anchors therefor
JP7227240B2 (en) 2017-10-31 2023-02-21 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド artificial heart valve
EP3703615B1 (en) 2017-10-31 2024-05-15 W. L. Gore & Associates, Inc. Transcatheter deployment systems and associated methods
CA3078606C (en) 2017-10-31 2023-09-05 W.L. Gore & Associates, Inc. Medical valve and leaflet promoting tissue ingrowth
US11497601B2 (en) 2019-03-01 2022-11-15 W. L. Gore & Associates, Inc. Telescoping prosthetic valve with retention element
EP3952790A1 (en) 2019-04-12 2022-02-16 W.L. Gore & Associates, Inc. Valve with multi-part frame and associated resilient bridging features

Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105492A (en) * 1958-10-01 1963-10-01 Us Catheter & Instr Corp Synthetic blood vessel grafts
US3425418A (en) * 1963-06-15 1969-02-04 Spofa Vereinigte Pharma Werke Artificial blood vessels and method of preparing the same
US3451996A (en) * 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3523807A (en) * 1966-11-25 1970-08-11 Mihaly Gerendas Method of making a cross-linked fibrin prosthesis
US3549409A (en) * 1969-04-28 1970-12-22 Cordis Corp Production of nonthrombogenic plastics
US3688317A (en) * 1970-08-25 1972-09-05 Sutures Inc Vascular prosthetic
US4118449A (en) * 1975-09-02 1978-10-03 The United States Of America As Presprented By The United States Department Of Energy Method of making a cellulose acetate low density microcellular foam
US4188188A (en) * 1978-09-27 1980-02-12 Bio-Rad Laboratories, Inc. High density lipoprotein cholesterol assay
US4229540A (en) * 1979-07-02 1980-10-21 Cutter Laboratories, Inc. Hydrolase purified from human plasma
US4229838A (en) * 1977-07-01 1980-10-28 Sumitomo Electric Industries, Ltd. Vascular prosthesis having a composite structure
US4321711A (en) * 1978-10-18 1982-03-30 Sumitomo Electric Industries, Ltd. Vascular prosthesis
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4548736A (en) * 1983-08-29 1985-10-22 Wisconsin Alumni Research Foundation Preparation of protein films
US4612337A (en) * 1985-05-30 1986-09-16 The Trustees Of Columbia University In The City Of New York Method for preparing infection-resistant materials
US4613665A (en) * 1982-02-09 1986-09-23 Olle Larm Process for covalent coupling for the production of conjugates, and polysaccharide containing products thereby obtained
US4623539A (en) * 1983-02-04 1986-11-18 Tunc Deger C Nutrient barrier polysaccharide compositions and method of use
US4680177A (en) * 1982-04-28 1987-07-14 Trustees of the Garfield Weston Trust for Research into Heart Surgery Processes for the production of blood products
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4768507A (en) * 1986-02-24 1988-09-06 Medinnovations, Inc. Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis
US4794002A (en) * 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4873308A (en) * 1988-09-30 1989-10-10 Medtronic, Inc. Biostable, segmented aliphatic polyurethanes and process therefor
US4886062A (en) * 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4920203A (en) * 1987-12-17 1990-04-24 Allied-Signal Inc. Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US4995893A (en) * 1988-06-23 1991-02-26 Pilkington Plc Method of making coatings on glass surfaces
US5010063A (en) * 1988-06-10 1991-04-23 Alfa Wasserman S.P.A. Heparin derivatives and process for their preparation
US5039529A (en) * 1987-05-27 1991-08-13 Kabivitrum Ab Novel heparin derivatives
US5041100A (en) * 1989-04-28 1991-08-20 Cordis Corporation Catheter and hydrophilic, friction-reducing coating thereon
US5059166A (en) * 1989-12-11 1991-10-22 Medical Innovative Technologies R & D Limited Partnership Intra-arterial stent with the capability to inhibit intimal hyperplasia
US5061276A (en) * 1987-04-28 1991-10-29 Baxter International Inc. Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US5104860A (en) * 1989-01-30 1992-04-14 Alfa Wassermann S.P.A. Heparin derivatives and process for their preparation
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5330500A (en) * 1990-10-18 1994-07-19 Song Ho Y Self-expanding endovascular stent with silicone coating
US5342605A (en) * 1992-05-01 1994-08-30 Sterling Winthrop Inc. Polymeric X-ray compositions containing iodinated polymeric beads
US5352434A (en) * 1992-05-01 1994-10-04 Sterling Winthrop Inc. X-ray contrast compositions containing a barium salt and film-forming materials
US5399318A (en) * 1993-01-27 1995-03-21 American Home Products Corporation Blood sampling apparatus containing an anticoagulant composition
US5451424A (en) * 1989-01-18 1995-09-19 Becton Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5510077A (en) * 1992-03-19 1996-04-23 Dinh; Thomas Q. Method of making an intraluminal stent
US5531735A (en) * 1994-09-27 1996-07-02 Hercules Incorporated Medical devices containing triggerable disintegration agents
US5534288A (en) * 1993-03-23 1996-07-09 United States Surgical Corporation Infection-resistant surgical devices and methods of making them
US5541305A (en) * 1991-01-16 1996-07-30 Toyo Boseki Kabushiki Kaisha Composition compatible with blood
US5554182A (en) * 1992-03-19 1996-09-10 Medtronic, Inc. Method for preventing restenosis
US5591199A (en) * 1995-06-07 1997-01-07 Porter; Christopher H. Curable fiber composite stent and delivery system
US5591227A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Drug eluting stent
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5634899A (en) * 1993-08-20 1997-06-03 Cortrak Medical, Inc. Simultaneous cardiac pacing and local drug delivery method
US5634946A (en) * 1988-08-24 1997-06-03 Focal, Inc. Polymeric endoluminal paving process
US5702682A (en) * 1995-12-01 1997-12-30 Hercules Incorporated Methods for preparing radiopaque medical devices
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5760200A (en) * 1987-09-18 1998-06-02 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5769884A (en) * 1996-06-27 1998-06-23 Cordis Corporation Controlled porosity endovascular implant
US5820918A (en) * 1996-07-11 1998-10-13 Hercules Incorporated Medical devices containing in-situ generated medical compounds
US5843146A (en) * 1997-04-30 1998-12-01 Medtronic Incorporated Adjustable medical lead anchor
US5848995A (en) * 1993-04-09 1998-12-15 Walder; Anthony J. Anti-infective medical article and method for its preparation
US6013099A (en) * 1998-04-29 2000-01-11 Medtronic, Inc. Medical device for delivering a water-insoluble therapeutic salt or substance
US6106454A (en) * 1997-06-17 2000-08-22 Medtronic, Inc. Medical device for delivering localized radiation
US6203536B1 (en) * 1997-06-17 2001-03-20 Medtronic, Inc. Medical device for delivering a therapeutic substance and method therefor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965909A (en) * 1975-04-22 1976-06-29 Medrad, Inc. Angiographic catheter and method of manufacture
GB2084466B (en) * 1980-10-06 1984-07-11 Mcnally Ronald Biocidal material
CH649916A5 (en) 1984-03-14 1985-06-28 Sulzer Ag Active compound store intended for insertion into a living body
IT1214609B (en) 1985-05-17 1990-01-18 Opocrin Spa HEXOSAMINOGLICANS DEPOLYMERIZED SULPHATES FOR ANTI-THROMBOTIC, FIBRINOLITHIC, ANTI-INFLAMMATORY ACTIVITIES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK505588D0 (en) 1988-02-26 1988-09-09 Jesper Hamburger MEDIUM AND USE OF SAME
US4955893A (en) 1988-05-09 1990-09-11 Massachusetts Institute Of Technologh Prosthesis for promotion of nerve regeneration
EP0366564B1 (en) 1988-10-28 1995-07-12 Terumo Kabushiki Kaisha Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
JPH05502179A (en) 1990-02-28 1993-04-22 メドトロニック　インコーポレーテッド Tubular organ drug elution device
EP0528971B1 (en) 1990-05-14 1999-09-01 JERNBERG, Gary R. Surgical implant and method incorporating chemotherapeutic agents
GB2268066A (en) * 1992-06-25 1994-01-05 Univ Manchester Catheter with porous matrix material
AU7019494A (en) 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
WO1995010989A1 (en) 1993-10-19 1995-04-27 Scimed Life Systems, Inc. Intravascular stent pump
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
DE69623455T2 (en) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth COATED DILATATOR FOR DISPOSING A MEDICINAL PRODUCT
US5763052A (en) 1995-08-22 1998-06-09 Optical Security Group, Inc. Informational article and an associated method
US5951586A (en) 1996-05-15 1999-09-14 Medtronic, Inc. Intraluminal stent
US5972027A (en) 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system

Patent Citations (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105492A (en) * 1958-10-01 1963-10-01 Us Catheter & Instr Corp Synthetic blood vessel grafts
US3425418A (en) * 1963-06-15 1969-02-04 Spofa Vereinigte Pharma Werke Artificial blood vessels and method of preparing the same
US3523807A (en) * 1966-11-25 1970-08-11 Mihaly Gerendas Method of making a cross-linked fibrin prosthesis
US3451996A (en) * 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3549409A (en) * 1969-04-28 1970-12-22 Cordis Corp Production of nonthrombogenic plastics
US3688317A (en) * 1970-08-25 1972-09-05 Sutures Inc Vascular prosthetic
US4118449A (en) * 1975-09-02 1978-10-03 The United States Of America As Presprented By The United States Department Of Energy Method of making a cellulose acetate low density microcellular foam
US4229838A (en) * 1977-07-01 1980-10-28 Sumitomo Electric Industries, Ltd. Vascular prosthesis having a composite structure
US4188188A (en) * 1978-09-27 1980-02-12 Bio-Rad Laboratories, Inc. High density lipoprotein cholesterol assay
US4321711A (en) * 1978-10-18 1982-03-30 Sumitomo Electric Industries, Ltd. Vascular prosthesis
US4229540A (en) * 1979-07-02 1980-10-21 Cutter Laboratories, Inc. Hydrolase purified from human plasma
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
US4613665A (en) * 1982-02-09 1986-09-23 Olle Larm Process for covalent coupling for the production of conjugates, and polysaccharide containing products thereby obtained
US4680177A (en) * 1982-04-28 1987-07-14 Trustees of the Garfield Weston Trust for Research into Heart Surgery Processes for the production of blood products
US4623539A (en) * 1983-02-04 1986-11-18 Tunc Deger C Nutrient barrier polysaccharide compositions and method of use
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4548736A (en) * 1983-08-29 1985-10-22 Wisconsin Alumni Research Foundation Preparation of protein films
US4612337A (en) * 1985-05-30 1986-09-16 The Trustees Of Columbia University In The City Of New York Method for preparing infection-resistant materials
US4794002A (en) * 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4768507A (en) * 1986-02-24 1988-09-06 Medinnovations, Inc. Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US5061276A (en) * 1987-04-28 1991-10-29 Baxter International Inc. Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US5039529A (en) * 1987-05-27 1991-08-13 Kabivitrum Ab Novel heparin derivatives
US5760200A (en) * 1987-09-18 1998-06-02 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4886062A (en) * 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4920203A (en) * 1987-12-17 1990-04-24 Allied-Signal Inc. Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5010063A (en) * 1988-06-10 1991-04-23 Alfa Wasserman S.P.A. Heparin derivatives and process for their preparation
US4995893A (en) * 1988-06-23 1991-02-26 Pilkington Plc Method of making coatings on glass surfaces
US5634946A (en) * 1988-08-24 1997-06-03 Focal, Inc. Polymeric endoluminal paving process
US4873308A (en) * 1988-09-30 1989-10-10 Medtronic, Inc. Biostable, segmented aliphatic polyurethanes and process therefor
US5451424A (en) * 1989-01-18 1995-09-19 Becton Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5104860A (en) * 1989-01-30 1992-04-14 Alfa Wassermann S.P.A. Heparin derivatives and process for their preparation
US5041100A (en) * 1989-04-28 1991-08-20 Cordis Corporation Catheter and hydrophilic, friction-reducing coating thereon
US5059166A (en) * 1989-12-11 1991-10-22 Medical Innovative Technologies R & D Limited Partnership Intra-arterial stent with the capability to inhibit intimal hyperplasia
US5330500A (en) * 1990-10-18 1994-07-19 Song Ho Y Self-expanding endovascular stent with silicone coating
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5541305A (en) * 1991-01-16 1996-07-30 Toyo Boseki Kabushiki Kaisha Composition compatible with blood
US5591227A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Drug eluting stent
US5510077A (en) * 1992-03-19 1996-04-23 Dinh; Thomas Q. Method of making an intraluminal stent
US5554182A (en) * 1992-03-19 1996-09-10 Medtronic, Inc. Method for preventing restenosis
US5571166A (en) * 1992-03-19 1996-11-05 Medtronic, Inc. Method of making an intraluminal stent
US5697967A (en) * 1992-03-19 1997-12-16 Medtronic, Inc. Drug eluting stent
US5599352A (en) * 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5352434A (en) * 1992-05-01 1994-10-04 Sterling Winthrop Inc. X-ray contrast compositions containing a barium salt and film-forming materials
US5342605A (en) * 1992-05-01 1994-08-30 Sterling Winthrop Inc. Polymeric X-ray compositions containing iodinated polymeric beads
US5399318A (en) * 1993-01-27 1995-03-21 American Home Products Corporation Blood sampling apparatus containing an anticoagulant composition
US5534288A (en) * 1993-03-23 1996-07-09 United States Surgical Corporation Infection-resistant surgical devices and methods of making them
US5848995A (en) * 1993-04-09 1998-12-15 Walder; Anthony J. Anti-infective medical article and method for its preparation
US5624411A (en) * 1993-04-26 1997-04-29 Medtronic, Inc. Intravascular stent and method
US5679400A (en) * 1993-04-26 1997-10-21 Medtronic, Inc. Intravascular stent and method
US5776184A (en) * 1993-04-26 1998-07-07 Medtronic, Inc. Intravasoular stent and method
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5634899A (en) * 1993-08-20 1997-06-03 Cortrak Medical, Inc. Simultaneous cardiac pacing and local drug delivery method
US5531735A (en) * 1994-09-27 1996-07-02 Hercules Incorporated Medical devices containing triggerable disintegration agents
US5591199A (en) * 1995-06-07 1997-01-07 Porter; Christopher H. Curable fiber composite stent and delivery system
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5702682A (en) * 1995-12-01 1997-12-30 Hercules Incorporated Methods for preparing radiopaque medical devices
US5769884A (en) * 1996-06-27 1998-06-23 Cordis Corporation Controlled porosity endovascular implant
US5820918A (en) * 1996-07-11 1998-10-13 Hercules Incorporated Medical devices containing in-situ generated medical compounds
US5843146A (en) * 1997-04-30 1998-12-01 Medtronic Incorporated Adjustable medical lead anchor
US6106454A (en) * 1997-06-17 2000-08-22 Medtronic, Inc. Medical device for delivering localized radiation
US6203536B1 (en) * 1997-06-17 2001-03-20 Medtronic, Inc. Medical device for delivering a therapeutic substance and method therefor
US6013099A (en) * 1998-04-29 2000-01-11 Medtronic, Inc. Medical device for delivering a water-insoluble therapeutic salt or substance
US6187370B1 (en) * 1998-04-29 2001-02-13 Medtronic, Inc. Medical device for delivering a therapeutic substance and method therefor

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US20080268011A1 (en) * 2004-09-24 2008-10-30 Helmut Goldmann Antimicrobial Implant with a Flexible Porous Structure
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8715339B2 (en) 2006-12-28 2014-05-06 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US20090192079A1 (en) * 2007-10-09 2009-07-30 Genzyme Corporation Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses

Also Published As

Publication number Publication date
WO1998057680A2 (en) 1998-12-23
EP0920342B1 (en) 2002-09-04
US6730120B2 (en) 2004-05-04
EP0920342A2 (en) 1999-06-09
WO1998057680A3 (en) 1999-03-11
US20010002435A1 (en) 2001-05-31
DE69807634T2 (en) 2003-05-08
DE69807634D1 (en) 2002-10-10
US6203536B1 (en) 2001-03-20

Similar Documents

Publication Publication Date Title
US6730120B2 (en) Medical device for delivering a therapeutic substance and method therefor
US6187370B1 (en) Medical device for delivering a therapeutic substance and method therefor
US7419696B2 (en) Medical devices for delivering a therapeutic agent and method of preparation
US6106454A (en) Medical device for delivering localized radiation
US5951586A (en) Intraluminal stent
US5599352A (en) Method of making a drug eluting stent
US5865814A (en) Blood contacting medical device and method
US5554182A (en) Method for preventing restenosis
US5824048A (en) Method for delivering a therapeutic substance to a body lumen
US5464650A (en) Intravascular stent and method
US6355055B1 (en) Endovascular support device and method of use
US5800507A (en) Intraluminal stent
BE1008260A6 (en) Amphiphile polyurethane charged with medicine which is coated onto vascularstents for the treatment of blood vessel constriction
US6746481B1 (en) Implatable device including a polyamino acid component

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION